Products

RapidReviewer

Turn your GitHub PRs into performance-ready evidence.

rapidreviewer.io Chrome Web StoreHR & Careers / Employee Engagement & Learning

Desktop
Mobile
Monthly visits
<5K
Oct 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
$1.26/mo
Lower than 97% of peersNiche median $19/mo
Creators
Unlinked
No verified creators
Launched
10mo ago
2026-02-06 · Est.

Traffic

Last 12 months
Monthly visitsData through Oct 2026
Events1 marketing move

Marketing moves

Launches, search & content, referrals, promotions
  • Launched on Product HuntLaunch

    Developers, let's automate those tedious performance reviews

    Feb 6 · 10mo agoLaunch page

Traffic sources

Oct 2026

Traffic breakdown

No traffic channel or country breakdown data for this website yet.

Search

Domain authority —Domain registered 2025-12-28

No search keyword data for this website yet.

Traffic data: Vaneform

Pricing

RapidReviewer
£0.99/month

Trial: None · Observed 2026-11-07 · Source page

Entry price $1.26/mo, Lower than 97% of peers; “Employee Engagement & Learning” median is $19/mo.View pricing benchmark

Website snapshots

Indexed 2026-02-06

Key pages

Desktop & mobile archive
Home
rapidreviewer.io/ Snapshot 2026-11-07

Questions & evidence

How much does RapidReviewer cost?
RapidReviewer: £0.99/month. Observed 2026-11-07. Check the source for current billing terms, usage limits and taxes.Source
How much website traffic does RapidReviewer get?
Vaneform estimates <5K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is RapidReviewer and what platforms does it support?
RapidReviewer is catalogued under Employee Engagement & Learning: Turn your GitHub PRs into performance-ready evidence. Supported platforms: Browser Extension.

Related products in this category

HR & Careers / Employee Engagement & Learning

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.